Drugs / AMLCTL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00808080 | Jan 2010 → Jun 2013 | acute myeloid leukemia | Thomas A. Lane, MD | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMLCTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00808080 ↗ |
| Modality | Cell therapy | “Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)” NCT00808080 ↗ |